Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency related reintervention rate of 1.3 per patient year.
InVera Medical, a medical device company focused on advancing minimally-invasive technologies for Chronic Venous Disease, ...
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully ...
Medtronic (NYSE:MDT) today announced new real-world data from a post-approval study of its In.Pact AV drug-coated balloon (DCB).
Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients April 28, 2026 8:00 AM ...
The data show a correlation between wound healing and better participation in social activities, better sleeping habits, and ...
Dr. Ozsvath discusses leadership in venous societies, community engagement in vascular care, venous research priorities, and ...
The National on MSN
Emirati recovers after rare stroke mistaken for headache
Abu Dhabi resident was initially sent home with painkillers ...
Please provide your email address to receive an email when new articles are posted on . Many variables make accurate prediction of hemodialysis start and AVF maturation nearly impossible. Several ...
The end-stage kidney disease device performed as well in the study as in a pivotal trial that supported FDA approval.
Transvenous embolisation is typically done under general anaesthesia but can also be done under local anaesthesia or conscious sedation. Venous access is achieved through the common femoral or ...
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results